Pfizer has partnered with a ‘computation-driven’ pharmaceutical technology company to develop a drug discovery platform powered by artificial intelligence (AI). Its collaboration with ...

The label for Moderna's respiratory syncytial virus (RSV) vaccine mResvia has been expanded to include adults aged 18 and over in the US, widening its earlier FDA approval for the over-60s only.

Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.

Biogen has started a phase 3 trial that it hopes will extend the label for its Skyclarys therapy for inherited neurological disease Friedreich's ataxia (FA) to include children as young as two.

Meet Dyasonic, a Marvel-inspired superhero with type 1 diabetes whose mission is to help patients feel "seen, understood, and represented".

US Senators Bernie Sanders and Angus King have introduced a bill that seeks to ban direct-to-consumer (DTC) advertising by the pharma industry.

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

1 Day. 20 Pharma Senior Speakers From GSK, Pfizer, AstraZeneca & More Explore Impactful, Value-Adding & Engaging Pharma Comms Strategies! Book 4 For The Price Of 3!

The credit crunch has increased cost pressures on the pharmaceutical industry, Capgemini suggests that part of its response could be to open up a dialogue about the wider healthcare agenda. These ...

The most successful pharma sales teams will be those that define and service customers in new ways. Those who are the most responsive and relevant to today's customers and influencers will reap ...

Bristol Myers Squibb has expanded its push into radiopharma by licensing a prostate cancer therapy developed by Philochem for $350m upfront.

Hannah Blake. pharmaphorum. Threshold Pharma is to go ahead with Phase 3 clinical trials of its only drug, TH-302, despite recent Phase 2 trials failing to show statistically significant ...